DS-1501 / Daiichi Sankyo - LARVOL DELTA

SITC 2021 | Targeting Siglec-15 with NC318 in Siglec-15-positive advanced solid tumors (VJOncology) - "Omid Hamid, MD...outlines the clinical benefit of targeting Siglec-15 with the monoclonal antibody NC318 in patients with Siglec-15-positive advanced solid tumors...This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C."

Interview • Video

Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use. (PubMed, Bone) - "We have produced rat monoclonal anti-Siglec-15 antibody (32A1) and successively generated humanized monoclonal anti-Siglec-15 antibody (DS-1501a) from 32A1...The beneficial balance of bone turnover caused by 32A1 might, at least in part, be responsible for the improvement in bone quality. This is the first report describing the effects of anti-Siglec-15 antibody in OVX rats; the findings suggest that this antibody could be an excellent candidate for treating osteoporosis, especially in continuation therapy after PTH treatment, due to its rapid action and unprecedented beneficial effects on bone quality."

Journal • PK/PD data • Orthopedics • Osteoporosis • Rheumatology

Anti-Siglec-15 antibody suppresses bone resorption by inhibiting osteoclast multinucleation without attenuating bone formation. (PubMed, Bone) - "We evaluated osteoclast activity using a pH-sensing probe and found that the bone resorptive ability of osteoclasts was lower following anti-Siglec-15 antibody treatment compared to after risedronate treatment. Our findings suggest that anti-Siglec-15 treatment may have potential as an anti-resorptive therapy for osteoporosis, which substantially inhibits the activity of osteoclasts while maintaining physiological bone coupling."

Journal • Osteoporosis • Rheumatology • NFATC1

"Also Daiichi Sankyo R&D pipeline in 2017 listed anti-siglec-15 MAb DS-1501 for osteoporosis https://t.co/Ijj3ooLzMt $NXTC" (@JacobPlieth)